Last reviewed · How we verify
Injection of autologous stem cells
Injection of autologous stem cells is a Biologic drug developed by Kenneth Peters, MD. It is currently in Phase 1 development.
At a glance
| Generic name | Injection of autologous stem cells |
|---|---|
| Sponsor | Kenneth Peters, MD |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Nausea
- Fatigue
- Neutrophil count decreased
- Platelet count decreased
- Constipation
- Hemoglobin decreased
- Headache
- Insomnia
- Procedural pain
- Back pain
- Arthralgia
- Vomiting
Key clinical trials
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
- Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (PHASE3)
- Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (PHASE3)
- Anterior Cruciate Ligament (ACL) Reconstruction With Autologous Fat Pad Derived Mesenchymal Stem Cells (PHASE1)
- A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia Major (PHASE2)
- Autologous SVF Therapy for Type 2 Diabetes (NA)
- A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma (PHASE1, PHASE2)
- Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Injection of autologous stem cells CI brief — competitive landscape report
- Injection of autologous stem cells updates RSS · CI watch RSS
- Kenneth Peters, MD portfolio CI
Frequently asked questions about Injection of autologous stem cells
What is Injection of autologous stem cells?
Injection of autologous stem cells is a Biologic drug developed by Kenneth Peters, MD.
Who makes Injection of autologous stem cells?
Injection of autologous stem cells is developed by Kenneth Peters, MD (see full Kenneth Peters, MD pipeline at /company/kenneth-peters-md).
What development phase is Injection of autologous stem cells in?
Injection of autologous stem cells is in Phase 1.
What are the side effects of Injection of autologous stem cells?
Common side effects of Injection of autologous stem cells include Nausea, Fatigue, Neutrophil count decreased, Platelet count decreased, Constipation, Hemoglobin decreased.
Related
- Manufacturer: Kenneth Peters, MD — full pipeline